Irradiated C57BL/ 6 (H-2b) recipients of T-cell-depleted (TCD) BALB/c (H-2d) bone marrow (BM) and recombinant interleukin-la (IL-la) (1 pg/d) had a significantly (P 5 .006) higher 100-day actuarial survival rate, accelerated hematopoietic recovery, and higher levels of alloengraftment than a group of transplanted control mice treated identically, but given phosphate-buffered saline (PBS). To elucidate the mechanisms involved with IL-la-induced promotion of alloengraftment and hematopoietic recovery, we performed sequential splenic FACS studies on transplanted mice and secondary transfer studies in syngeneic mice given IL-laor PBS. Splenic phenotyping showed that recipients of IL-la had a higher proportion of donor granulocytes (52% v 19%) as compared with PBS controls as early as 7 days after bone marrow transplantation (BMT). On day 11 post-BMT, recipients of IL-la had a more than fourfold increase in splenocyte number, which included a higher percentage (90% v 59%) of donor cells, especially donor granulocytes (52% v 32%), and a sevenfold increase in donor T cells as compared with controls. Host T-cell numbers were not affected. Taken N PREVIOUS REPORTS, we have examined the in vivo I effects of hematopoietic growth factors that are ostensibly single lineage-restricted in their action (eg, granulocyte colony-stimulating factor [G-CSF],' macrophage-CSF [M-CSFI2), or factors that produce multiple lineage-reactions (eg, granulocyte-macrophage-CSF [GM-CSFI3) in established murine models of allogeneic bone marrow transplantation (BMT) in which donor T-cell depletion (TCD) was used to induce a reduction in the rate of alloengraftment.4 Donor alloengraftment was reduced with GM-CSF and M-CSF, but was not affected by G-CSF. In the present studies, we have assessed the in vivo effect of interleukin-la (IL-la) because of its known properties of facilitating the From the MN 55455. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1992 by The American Society of Hematology. 0006-4971 l92/8006-OO20$3 .00 IO together, these data suggest that IL-la stimulated bipotential (myeloid and lymphoid) donor cell engraftment. In a syngeneic BMT system, administration of IL-la resulted in a higher incidence of survival when recipients were transplanted with BM cells, indicating that IL-la administration probably either expanded or potentiated engraftment of a committed progenitor cell pool. Secondary transfer experiments using marrow from IL-la-treated mice showed that the number of day 12 colony-forming unit-spleen (CFU-S) cells was unaltered compared with untreated control mice, suggesting that more primitive, albeit committed, hematopoietic progenitor cells were not affected. We also examined the potential additive effects of IL-la and granulocyte-macrophage colony-stimulating factor (GM-CSF) administered in combination (for 14 days). Mice receiving a suboptimal amount of IL-la along with GM-CSF had significantly higher levels of donor alloengraftment (92%) with superior hematopoietic recovery, as compared with mice receiving either IL-la(57Y0) or GM-CSF (18%) alone.
Irradiated C57BL/ 6 (H-2b) recipients of T-cell-depleted (TCD) BALB/c (H-2d) bone marrow (BM) and recombinant interleukin-la (IL-la) (1 pg/d) had a significantly (P 5 .006) higher 100-day actuarial survival rate, accelerated hematopoietic recovery, and higher levels of alloengraftment than a group of transplanted control mice treated identically, but given phosphate-buffered saline (PBS). To elucidate the mechanisms involved with IL-la-induced promotion of alloengraftment and hematopoietic recovery, we performed sequential splenic FACS studies on transplanted mice and secondary transfer studies in syngeneic mice given IL-laor PBS. Splenic phenotyping showed that recipients of IL-la had a higher proportion of donor granulocytes (52% v 19%) as compared with PBS controls as early as 7 days after bone marrow transplantation (BMT). On day 11 post-BMT, recipients of IL-la had a more than fourfold increase in splenocyte number, which included a higher percentage (90% v 59%) of donor cells, especially donor granulocytes (52% v 32%), and a sevenfold increase in donor T cells as compared with controls. Host T-cell numbers were not affected. Taken N PREVIOUS REPORTS, we have examined the in vivo I effects of hematopoietic growth factors that are ostensibly single lineage-restricted in their action (eg, granulocyte colony-stimulating factor [G-CSF],' macrophage-CSF [M-CSFI2), or factors that produce multiple lineage-reactions (eg, granulocyte-macrophage-CSF [GM-CSFI3) in established murine models of allogeneic bone marrow transplantation (BMT) in which donor T-cell depletion (TCD) was used to induce a reduction in the rate of alloengraftment.4 Donor alloengraftment was reduced with GM-CSF and M-CSF, but was not affected by G-CSF. In the present studies, we have assessed the in vivo effect of interleukin-la (IL-la) because of its known properties of facilitating the together, these data suggest that IL-la stimulated bipotential (myeloid and lymphoid) donor cell engraftment. In a syngeneic BMT system, administration of IL-la resulted in a higher incidence of survival when recipients were transplanted with BM cells, indicating that IL-la administration probably either expanded or potentiated engraftment of a committed progenitor cell pool. Secondary transfer experiments using marrow from IL-la-treated mice showed that the number of day 12 colony-forming unit-spleen (CFU-S) cells was unaltered compared with untreated control mice, suggesting that more primitive, albeit committed, hematopoietic progenitor cells were not affected. We also examined the potential additive effects of IL-la and granulocyte-macrophage colony-stimulating factor (GM-CSF) administered in combination (for 14 days). Mice receiving a suboptimal amount of IL-la along with GM-CSF had significantly higher levels of donor alloengraftment (92%) with superior hematopoietic recovery, as compared with mice receiving either IL-la(57Y0) or GM-CSF (18%) alone. 0 1992 by The American Society of Hematology.
proliferation of earlier multilineage hematopoietic progenitor cells in vitro6-11 and in vivo circulating leukocyte^.^ IL-1 administered in vivo accelerates neutrophil recovery in rodent~,l~-~' and primates29 that have received myelosuppressive chemotherapy or radiation.
Oppenheim et a1 have demonstrated that injections of IL-1 before or after lethal total body irradiation (TBI) can improve survival rates in recipients infused with limited numbers of TCD allogeneic BM.25 These investigators presented data which suggested that IL-1 administration post-BMT may be associated with a tendency toward higher donor cell engraftment in the strain combination studied. However, since the surviving control transplanted mice not treated with IL-1 had a significantly lowered survival rate and were also repopulated with a majority of donor cells, definitive conclusions as to the potential engraftmentpromoting effect of IL-1 were not possible. Therefore, we undertook the present study to investigate the alloengraftment-promoting effects of IL-la post-BMT. We also assessed which lineages of cells were most influenced by IL-la post-BMT and determined the additive capabilities of IL-la with GM-CSF, which has been previously reported to synergize with suboptimal amounts of IL-18 in radioprotection experiments.
We chose a fully allogeneic strain combination in which donors (BALB/c) differed from the recipients (C57BL/6) at the major histocompatibility complex (MHC). A detailed analysis of the post-BMT hematopoiesis in recipients of TCD allogeneic or nondepleted syngeneic grafts was performed for further insight into the mechanism(s) involved in IL-la-mediated alteration in alloengraftment post-BMT.
Our data conclusively demonstrate for the first time that IL-la does indeed have a potent effect in promoting engraftment of fully allogeneic marrow and provide evi-dence that the effect of IL-la is on the engraftment of cells of both myeloid and lymphoid lineages.
MATERIALS AND METHODS

BALB/c (H-2d) donors were purchased from
Charles River (Wilmington, MA) and C57BL/6 (H-2b) recipients were purchased from the Jackson Laboratory (Bar Harbor, ME). Animals were housed in conventional cages with filter lids and fed a fat-supplemented diet and antibiotic-supplemented water for 2 days pre-BMT and for 30 days post-BMT. Donors (age, 5 to 8 weeks) and recipients (10 to 12 weeks) were female mice. TBI was administered from a Philips RT 250 Orthovoltage Therapy Unit (Philips Medical Systems, Germany) filtered through 0.35-mm Cu. The final absorbed dose rate was 0.41 Gy/min at 225 kV and 17 mA to a total dose of 6.0 to 7.5 Gy per mouse for recipients of BALB/c marrow, and 9.0 Gy per mouse for nonmanipulated syngeneic BM. Our transplant methodology for the irradiation and transplantation of donor cells has been described in detail.1,3,4 Briefly, donor marrow was collected into RPMI 1640 medium by flushing it from the shafts of femurs and tibias. The cells were resuspended, and clumps of debris were allowed to settle out. Ex vivo TCD of 18 x lo6 BALB/c BM cells per recipient was performed using anti-Thy 1.2 monoclonal antibody (hybridoma 30-H12, rat IgG2b; American Tissue Type Culture Collection, Rockville, MD) plus complement as previously des~ribed.',~,~ These cell doses were chosen based on our prior experience?" After treatment, all aliquots were washed, resuspended, and adjusted for caudal vein injection. For syngeneic transplants, los to lo6 nondepleted marrow cells were infused into each recipient. For day 12 colony-forming unit-spleen (CFU-S) determination, 0.25 or 1.0 x lo6 BM cells were infused into irradiated (7.5 Gy TBI by cesium 137 delivered at a dose rate of 85 cGy/min) syngeneic C57BL/6. Twelve days post-BMT, mice were killed and spleens were placed into Bouin's solution to facilitate enumeration of colonies Recombinant IL-la is a highly purified, recombinant, nonglycosylated human protein with high specific activity ( lo8 U/mg) determined by EL4.6.1 assay,31 and was produced in
Escherichia
Recombinant GM-CSF is a highly purified, glycosylated protein produced in yeast with high specific activity (5 x lo7 U/pg) as previously described? Both cytokines were produced by Immunex (Seattle, WA).
In vivo administration of I L -l a For continuous subcutaneous delivery of IL-la, a 14-day mini-osmotic pump (ALZA, Palo Alto, CA) was implanted (under general anesthesia) in control and experimental mice on the day of BM transfer as described.'~~ For long-term chimerism experiments, 15 to 18 mice per group were implanted with pumps loaded with a 200-pL vol containing 14 pg IL-1. The delivery rate was 1 pg/d (0.5 pL/h).
Chimerism of peripheral blood mononuclear cells was analyzed at 6 to 8 weeks post-BMT. Engraftment was quantitated by analyzing the cell surface binding of anti-H-2 monoclonal antibody linked to fluorochromes on a FACScan (Becton Dickinson, Mountain View, CA). For quantification of donor cell engraftment, a11ti-H-2~ (hybridoma 34-5-88, mouse IgG2a),34 provided by Dr David Sachs (National Institutes of Health, Bethesda, MD),3s was directly conjugated to fluorescein isothiocyanate (FITC). For host cell quantification, a11ti-H-2~ (hybridoma EH144, mouse IgG), provided by Dr T.V. Rajan (University of Connecticut, Farmington, CT) was directly conjugated to phycoerythrin (PE). The peripheral blood mononuclear cells were incubated with 2.4G2 to block Fc and then incubated with an optimal concentration of fluorochrome-labeled monoclonal antibody for 45 minutes at 4°C. Cells were washed three times and resuspended for analysis. An
BMTprocedure.
Cytokines.
Long-term engrafiment as measured by flow cytomeoy.
anti-human CD7 (hybridoma 3AlE, mouse IgG), provided by Dr Barton Haynes (Duke University, Durham, NC),37 was conjugated to FITC or PE to determine control (background) staining. Background values were subtracted from values obtained with relevant antibodies as previously described?8 Flow cytometry was performed on a FACScan. Ten thousand events (determined by fonvard light scatter) were analyzed. Hematologic and chimerism data were analyzed as individual values, with data presented as the mean 2 1 SEM.
Hematologic evaluation of recipients post-BMT.
RESULTS
Improved survival, hematopoietic recovery, and alloengrafiment in C57BL16 recipients of BALBIc TCD BMand 14-day continuous subcutaneous infusions of IL-la (1 Kgld). Cumulative survival data from three experiments in which
C57BLl6 mice were transplanted with BALBIc marrow and given a continuous subcutaneous infusion of IL-la (1 Kg/d) are depicted in Fig 1. Survival was significantly prolonged for recipients of IL-la in comparison to recipients of phosphate-buffered saline (PBS). The beneficial effect of IL-la on survival was most evident in the first 2 weeks post-BMT despite the toxic side effects of IL-la that led to a significant weight loss (23% to 24% pre-BMT body weight) as compared with the PBS group (< 10% of the pre-BMT body weight).
We studied hematopoietic recovery in two of the three For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Table 1 ND  ND  ND  ND  ND  IL-1 1 kg 32.5 f 7.0* 29.9 f 6.5* 2. Table 1) . As compared with PBS controls, recipients of IL-la had an increase in the number of leukocytes on day 14, due primarily to an increase in circulating neutrophils. In comparison to normal, nontransplanted C57BL/6 mice implanted with 14-day pumps containing PBS, recipients of IL-la at this time period had an approximately twofold to threefold increase in total leukocytes and a 25-fold increase in total neutrophils (data not shown). Absolute lymphocyte counts (ALC) were increased to a lesser, but still significant (P < .005), extent on day 14. By days 28 or 59, the relative neutrophilia was still present, but to a lesser degree than observed earlier. Hematocrit levels were comparable at all time periods post-BMT.
. Effect of a 14-Day Continuous Subcutaneous Infusion of High-Dose IL-la on Post-BMT Hematopoietic Reconstitution of C57BL/6 Recipients of TCD BALB/c Grafts
Recipients of IL-la also displayed a significant (P I .006) increase in chimerism as compared with PBS controls (Table 2) . Overall, recipients of IL-la had increases of mean donor cell percentages from 27% to 74%, and decreases of mean host cell percentages from 69% to 22%, as compared with the PBS control m i c 
Lineage of splenic hematopoietic cells obtained from
C57BLI6 recipients of BALBIc TCD BM and a 14-day subcutaneous infusion of IL-la (1 pgld) post-BMT.
Morphological analysis of peripheral blood cells suggested that the major effects of IL-la were on the myeloid lineage. We performed splenectomies after initiation of IL-la infusions to analyze in more detail, and in a kinetic fashion, the effects of IL-la on splenic myeloid and lymphoid lineages (Table 3) . In recent studies,3O we have observed that the For personal use only. on November 16, 2017. by guest www.bloodjournal.org From process of alloengraftment has been completed between days 7 and 11 post-BMT in this model system, and early post-BMT FACS analysis of the spleen provides considerable insight as to donor and host cell populations, which predict long-term alloengraftment in the periphery.
On day 7 post-BMT, as in previous studies, there was a predominance of donor cells in tested groups with IL-la and PBS, although fewer host cells were noted in recipients of IL-la as compared with controls. Donor granulocytes (stained by monoclonal antibody 8C5) comprised a higher proportion of the phenotypically identifiable cell populations in recipients of IL-la as compared with PBS. No NK1.1+ cells were detected at this or any other time period post-BMT (data not shown), although it should be noted that nontransplanted C57BLl6 mice have 2% or less NK1.1+ cells (data not shown). There was also a twofold increase in the proportion and absolute number of host CD4+ cells (which comprised the largest fraction of T cells) in control as compared with IL-la-treated recipients (data not shown).
By day 11 post-BMT, recipients in the IL-la group had a substantially lower proportion of host cells and higher proportions of donor cells, a finding that is consistent with our subsequent observations that long-term chimerism was positively affected by IL-la. In contrast to host lymphoid cells, donor lymphoid cells were preferentially expanded by IL-la with a greater than sevenfold increase in the absolute number of donor T cells. The donor and host T-cell populations were evenly distributed between CD4+ and CD8+ cells in both groups at this and subsequent time periods (data not shown). At this time, donor granulocytes and the lymphoid cell populations were expanded similarly.
By day 14 post-BMT, the engraftment process appeared to be completed because recipients in the PBS group had 11% donor cells, while IL-la-treated recipients had 90% donor cells. Interestingly, analysis of the lymphoid cells showed strikingly higher proportions and absolute numbers of host CD3+ T cells (sixfold higher) in the PBS group as compared with the IL-la-treated group.
A significant (P I .0006) increase long-term (6 to 8 weeks post BMT) alloengraftment in peripheral blood was observed with IL-la treatment in this experiment, just as observed in the experiments depicted in Table 2 (data not shown). Mean donor cell number increased from 13% in the PBS controls to 79% in the recipients of IL-la, while mean host cell number decreased from 83% to 19%.
To assess immunoreconstitution 2 months post-BMT, donor and third-party (B1O.BR) skin grafts were placed on five recipients in the PBS pump control group and on five recipients in the IL-la-treated group. Analysis of mean donor and host cell percentages indicated that the controls had autologous recovery of their marrow grafts (0% donor, 97% host) and IL-la-treated recipients had all accepted their grafts (93% donor, 4% host). All controls rejected donor and third-party grafts, while all IL-la recipients accepted donor, and rejected third-party grafts, indicating that these mice were immunocompetent and specifically tolerant. The skin grafts were observed twice weekly for 27 days.
Effect of IL-la (1 pgld) continuous subcutaneous infusion on survival, hematopoietic recovery, and secondary BM transfer experiments in C57BL I6 recipients receiving syngeneic BMT.
We tested effects of IL-la infusion in the syngeneic BMT setting. We did so to study the hematopoietic recovery and secondary BM transfer without the influence of the alloenvironment. Also, we knew that data from the syngeneic model would be a useful control for evaluating the influence of the alloenvironment on IL-la administration. BM doses used were 105 to lo6 per recipient (n = 10 per group). At the highest BM dose (106), recipients of IL-la (1 pg/d) had significantly (P = .00083) higher actuarial survival than PBS controls (100% v 30%, respectively) on day 55. At the 3 X lo5 BM cell dose, recipients of IL-la had improved survival as compared with PBS controls (50% v 30%) (Fig 2) . However, at the lowest BM dose tested, no beneficial effect of IL-la was observed.
Hematologic studies showed that recipients of the highest BM dose (lo6) and IL-la had an eightfold increase in mean numbers of circulating leukocytes (10.3 v 1.6 X lo6/ pL), reflected by a 24-fold increase in ANC (9.4 v 0.4 x lo6/ pL), but not ALC on day 17 post-BMT (data not shown). Hematocrit values (31% v 40%) were significantly lower in the IL-la group. At a BM dose of 3 x lo5, differences in total leukocytes were less striking. Again, hematocrit values were significantly lower in the IL-la group (24% v 36%). Due to the low survival in recipients of 105 BM cells, group comparisons could not be made. Hematocrit values in the PBS group were only 20%.
Fifty-five days after syngeneic BMT, the recipients of lo6 BM and PBS or IL-la described above were killed and used as donors in secondary transfer experiments. For secondary transplants, three surviving mice that received PBS and three recipients of IL-la that had the highest day 17 For personal use only. on November 16, 2017. by guest www.bloodjournal.org From peripheral blood leukocyte counts from the experiment shown in Table 4 , were chosen as BM donors. The total number of BM cells obtained from the primary recipients to be used for secondary transfer was comparable in the two groups of mice (data not shown). BM differentials showed a significantly (P = .01) higher proportion of mature granulocytes in the IL-la-treated group as compared with the PBS group (66% v 52%), while immature granulocyte numbers were equivalent. There was also a statistical trend (P = .08) toward lower numbers of immature erythroid cells in the IL-la-treated group as compared with the PBS group (7% v 16%). Splenocyte number and function in the primary recipients was also examined at the time of BM harvesting for secondary BMT. Interestingly, splenocyte number in the PBS group was significantly (P < .05) higher than in the recipients of IL-la (68 v 14 x lo6) . Splenocyte phytohemagglutinin responses (range of mean cpm,, in both groups, 58 to 68 x 105) were equivalent in the two groups.
Secondary syngeneic BMT and day 12 CFU-S frequency estimates were performed (Table 5 ). One million BM cells from each syngeneic donor were used to reconstitute five secondary recipients for the CFU-S assay and also infused into a separate five recipients for syngeneic BMT. One month post-BMT, secondary recipients of IL-la-treated primary BM grafts had significantly (P < .005) lower numbers of circulating leukocytes, with sixfold lower levels of neutrophils and 2.5-fold lower levels of lymphocytes, significantly (P < .005) lower hematocrit values, and worse survival (87% v 53%) than recipients of BM from PBStreated mice. No differences in day 12 CFU-S formation were noted in recipients given cells from IL-la-treated or PBS-treated donors.
Effect of simultaneous subcutaneous infusion of IL-la and GM-CSF. C57BL/6 mice transplanted with BALB/c TCD BM were given a continuous subcutaneous infusion of IL-la (0.3 pg/d) and/or murine GM-CSF (0.3 pg/d) ( Table 6 ). Mice that received both cytokines in combination had significantly greater alloengraftment than mice receiving IL-la (0.3 pg/d) alone, GM-CSF (0.3 pg/d) alone, or PBS (P = .001, P = .038, and P < .001, respectively).
Hematopoietic parameters were also monitored in these recipients ( Table 7) . On day 7 post-BMT, a twofold to threefold elevation in leukocyte numbers was observed in recipients of IL-la (0.3 pg/d) with or without GM-CSF. NO elevations in leukocyte numbers were observed in recipients of GM-CSF alone. Cells of the neutrophil lineage accounted for the majority of the circulating leukocytes in recipients that had elevated leukocyte numbers.
By day 14 post-BMT, recipients of IL-la (0.3 pg/d) had leukocyte numbers that were 68-to 115-fold greater than PBS controls. However, an even higher number of leukocytes was observed when IL-la (0.3 pg/d) was combined with GM-CSF (0.3 pg/d). The majority of leukocytes in both groups consisted of neutrophils. By day 28, leukocytes and ANC values were identical in mice treated with cytokines or PBS.
As compared with the PBS group, all regimens yielded no significant differences in long-term survival (range, 53% to 73%). However, survival in the first 28 days post-BMT was improved in mice given the combination of cytokines (100%) or single cytokines (86%) as compared with the PBS group (73%). A 7-day course of IL-la was followed by a 7-day course of GM-CSF. C57BL/6 mice (15 per group) were irradiated and transplanted with BALB/c TCD BM. Recipients of IL-la for 7 days with or without a subsequent 7-day infusion of GM-CSF had similar survival (100% and 93%, respectively) and alloengraftment (both groups had 92% mean donor and 4% mean host mononuclear cells in the peripheral blood) (data not shown). The values for the PBS control group were significantly lower, with 60% survival and 34% mean donor/61% mean host alloengraftment.
Effect of sequential delivery of IL-la and GM-CSF. DISCUSSION The peripheral blood manifestations of IL-la administration by continuous subcutaneous infusion in allogeneic BM recipients were striking. In IL-la-treated mice, ANC values were 10-to 38-fold higher than in transplanted mice given PBS, and higher than for normal nontransplanted controls. It is likely that as a consequence of the several effects of IL-la administration, including the improved hematopoietic recovery, increased intracellular and systemic scavenger a~t i v i t y , 4~,~~ and enhanced resistance to infectious 0rganisms,4~ a survival advantage was observed. In other studies, we observed that the injection of 14 daily intraperitoneal doses of IL-la (0.1 kg/d) (n = 18) resulted in a highly significant (P = .005) decreased survival rate as compared with PBS-injected controls (n = IS), suggesting that for a 14-day administration schedule, continuous subcutaneous administration is favorable. Thus, we believe that higher IL-la peaks lead to more systemic toxicity. For personal use only. on November 16, 2017. by guest www.bloodjournal.org From BM collected from primary transplanted recipients of PBS or rlL-1 (Table 6 ) was used as a source of donor cells for secondary transplantation. A portion of the marrow was used for day 12 CFU-S determination by injecting the indicated number of cells into irradiated (7.5 Gy TBI) C57BL/6 recipients that were not further manipulated. Colony number was determined as described in Materials and Methods. For long-term reconstitution experiments, 106 BM cells from these same primary recipients were injected into irradiated (9.0 Gy TBI) C57BL/6 recipients as described in the Methods. Values represent the mean k 1 SEM. Values for day 29 post-BMT data are X I O -~/~L for WBC, ANC, and ALC, and percentage for HCT. Abbreviations are as in Table 1. *P < .05. t P < ,005.
Table 4. Hematopoietic Analysis of Mice Given Syngeneic BMTs and IL-la and Used for Secondary Transfer Studies
Regarding survival of mice given syngeneic BMT, we found that mice given higher numbers of BM cells and IL-la showed a survival advantage. Mice given lower cell numbers and IL-la had a survival disadvantage. This was likely related to (1) the added stress of having limited marrow cells (insufficient to generate appropriate hematopoietic recovery, especially erythroid recovery), and (2) the inherent toxicity of IL-la, which includes significant weight loss, diarrhea, hypothermia, and fluid or electrolyte imbal-Post-BMT IL-la administration at 1 Fg/d induced a highly significant promotion of alloengraftment, while IL-la at lower doses (0.01 or 0.1 Fg/d) was ineffective in stimulating alloengraftment or hematopoiesis (data not shown). A modest peripheral lymphocytosis was also observed in IL-la-treated recipients. Because IL-la injections in rodents have been shown to induce a peripheral lymphopenia (perhaps with splenic localization of lymphocytes) at the time of ne~trophilia:~ we carefully examined the spleen to determine if there was a more pronounced relative lymphocytosis present in recipients of IL-la as compared with PBS controls. We did not observe a difference in the number of host T cells present in the spleen post-BMT in recipients of IL-la or PBS. However, the total number of donor lymphoid cells was higher early post-BMT in the IL-la group as compared with PBS controls. In addition, an increase in ance?, 45, 46 3 9 2 1 0.720.2  0.520.2 0.220.1 2 9 2 2 2 . 9 k 0 . 4 1 . 6 k 0 . 3 1 . 2 2 0 . 2 3 8 t 1  IL-l(0.3) 0 . 4 k O . l t ND ND 4 0 k l 1 8 . 9~6 . 3 ' 17.4k5.9' 1 . 4 k O . 5 ' 2 9 k 2 5 . 6 2 1 . 0 4 . 3 2 0 . 7 1.320.3 3 8 formation, and, in most studies, peripheral blood neutrophil count~.'3,~6,~~,21-~3,6~ Moreover, an increased mobilization of BM and peripheral blood neutrophils known to be induced by IL-1 administration may have substantially contributed to the n e~t r o p h i l i a~~ in the setting of equivalent stimulation and expansion of progenitor cells, which can give rise to both lymphoid and myeloid cells. Peripheral blood neutrophils indeed have IL-1 receptors, which may be important in mediating the inflammatory effects of IL-L70 Finally, IL-1 also induces stromal cells to produce granulocyte/macrophage colony-stimulating activity.48
Our experience with the syngeneic model suggests that IL-la-induced neutrophilia is mediated through the stimulation of BM neutrophil production, rather than increased mobilization of BM or peripheral blood neutrophils. In primary marrow transfers, IL-la infusion increased hematopoietic recovery, especially of neutrophils in the first month post-BMT. At 2 months post-BMT, there was a relative decrease in total leukocyte numbers in recipients of IL-la as compared with controls. At this time, secondary transfer experiments indicated that there was no change in the total number or proportion of BM day 12 CFU-S cells. As compared with recipients of grafts not exposed to IL-la in vivo, recipients of BM from IL-la-treated donors had significantly lower leukocyte numbers, primarily neutrophils, and a significant anemia, suggesting that fewer stem cells were indeed present in the marrow of IL-1-treated mice. Morphologic examination of the BM obtained for secondary transfer showed a higher proportion of mature neutrophils and lower numbers of erythroid and lymphoid cells. Because day 12 CFU-S cells actually represent committed progenitor cells71 and not long-term reconstituting stem cells, these data suggest that IL-la has altered the direction of differentiation, perhaps by diverting donor progenitor cells away from the exythroid precursor cells toward terminally differentiated myeloid cells, with a net result that the number of day 12 CFU-S is not significantly affected.
In our final series of studies, we tested the effects of IL-la given in combination with GM-CSF. IL-1 has been previously reported in vitro to syngergize with GM-CSF in the proliferation of hematopoietic cells. 64 In combination cytokine experiments, we did note an increased beneficial effect of IL-la plus GM-CSF on early post-BMT survival, alloengraftment, and hematopoietic recovery in instances where suboptimal amounts of IL-la were coadministered with GM-CSF. The improved alloengraftment effect of IL-la plus GM-CSF administration is especially interesting when comparing these data with our present and previous studies demonstrating that GM-CSF alone in this setting leads to a predilection for autologous reconstitution? In experiments in which IL-la was administered first to stimulate hematopoietic progenitor cells, which could then be driven by GM-CSF, we observed no evidence of additive or synergistic effects such as has been described for nonhuman primates receiving IL-3 followed by GM-CSF.72 
